Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Relationship between Size of the Foveal Avascular Zone and Carbohydrate Metabolic Disorders during Pregnancy.

Sugimoto M, Wakamatsu Y, Miyata R, Matsubara H, Kondo M, Kamimoto Y, Ikeda T.

Biomed Res Int. 2019 Nov 4;2019:3261279. doi: 10.1155/2019/3261279. eCollection 2019.

2.

Changes in VEGF-related factors are associated with presence of inflammatory factors in carbohydrate metabolism disorders during pregnancy.

Sugimoto M, Kondo M, Kamimoto Y, Ikeda T, Cutler A, Mariya A, Anand-Apte B.

PLoS One. 2019 Aug 15;14(8):e0220650. doi: 10.1371/journal.pone.0220650. eCollection 2019.

3.

Synthesis of MOR Zeolite/Magnetite Composite via Seed Assisted Method.

Hagio T, Nijpanich S, Kunishi H, Yamaoka K, Phouthavong V, Kamimoto Y, Ichino R, Iwai K.

J Nanosci Nanotechnol. 2019 Oct 1;19(10):6841-6848. doi: 10.1166/jnn.2019.17123.

PMID:
31027039
4.

Retrospective study of pregnancies in women with Thr331Ala fibrinogen polymorphisms.

Okumura A, Tanaka H, Tanaka K, Katsuragi S, Kamimoto Y, Ikeda T.

J Matern Fetal Neonatal Med. 2019 Mar 19:1-6. doi: 10.1080/14767058.2019.1590329. [Epub ahead of print]

PMID:
30829091
5.

Tadalafil treatment in mice for preeclampsia with fetal growth restriction has neuro-benefic effects in offspring through modulating prenatal hypoxic conditions.

Tachibana R, Umekawa T, Yoshikawa K, Owa T, Magawa S, Furuhashi F, Tsuji M, Maki S, Shimada K, Kaneda MK, Nii M, Tanaka H, Tanaka K, Kamimoto Y, Kondo E, Kato I, Ikemura K, Okuda M, Ma N, Miyoshi T, Hosoda H, Endoh M, Kimura T, Ikeda T.

Sci Rep. 2019 Jan 18;9(1):234. doi: 10.1038/s41598-018-36084-x.

6.

TADAFER II: Tadalafil treatment for fetal growth restriction - a study protocol for a multicenter randomised controlled phase II trial.

Umekawa T, Maki S, Kubo M, Tanaka H, Nii M, Tanaka K, Osato K, Kamimoto Y, Tamaru S, Ogura T, Nishimura Y, Kodera M, Minamide C, Nishikawa M, Endoh M, Kimura T, Kotani T, Nakamura M, Sekizawa A, Ikeda T; TADAFER study group.

BMJ Open. 2018 Oct 30;8(10):e020948. doi: 10.1136/bmjopen-2017-020948.

7.

Safety trial of tadalafil administered for the treatment of preeclampsia.

Furuhashi FH, Tanaka H, Kaneda MK, Maki S, Nii M, Umekawa T, Osato K, Kamimoto Y, Ikeda T.

J Matern Fetal Neonatal Med. 2020 Jan;33(1):167-170. doi: 10.1080/14767058.2018.1487946. Epub 2018 Jul 22.

PMID:
29886797
8.

In utero spontaneous bladder rupture in a fetus with posterior urethral valve: A case report of prenatal diagnosis and management.

Magawa S, Tanaka H, Nii M, Maki S, Kamimoto Y, Ikeda T.

J Obstet Gynaecol Res. 2018 Jul;44(7):1318-1321. doi: 10.1111/jog.13646. Epub 2018 Apr 19.

PMID:
29673009
9.

Management of fetal growth restriction using the contraction stress test: a case-control study.

Tanaka H, Furuhashi FH, Toriyabe K, Matsumoto T, Magawa S, Nii M, Watanabe J, Tanaka K, Umekawa T, Kamimoto Y, Ikeda T.

J Matern Fetal Neonatal Med. 2019 Oct;32(19):3221-3225. doi: 10.1080/14767058.2018.1461313. Epub 2018 Apr 18.

PMID:
29614894
10.

Placental growth factor as a predictor of the efficacy of tadalafil treatment for fetal growth restriction.

Kubo-Kaneda M, Tanaka H, Maki S, Nii M, Umekawa T, Osato K, Kamimoto Y, Kondo E, Ikeda T.

J Matern Fetal Neonatal Med. 2019 Sep;32(17):2879-2882. doi: 10.1080/14767058.2018.1450863. Epub 2018 Mar 26.

PMID:
29580120
11.

Cardiac function and tadalafil used for treating fetal growth restriction in pregnant women without cardiovascular disease.

Tanaka K, Tanaka H, Maki S, Kubo M, Nii M, Magawa S, Hatano F, Tsuji M, Osato K, Kamimoto Y, Umekawa T, Ikeda T.

J Matern Fetal Neonatal Med. 2019 Aug;32(15):2460-2462. doi: 10.1080/14767058.2018.1438401. Epub 2018 Feb 20.

PMID:
29415591
12.

Tadalafil Improves L-NG-Nitroarginine Methyl Ester-Induced Preeclampsia With Fetal Growth Restriction-Like Symptoms in Pregnant Mice.

Yoshikawa K, Umekawa T, Maki S, Kubo M, Nii M, Tanaka K, Tanaka H, Osato K, Kamimoto Y, Kondo E, Ikemura K, Okuda M, Katayama K, Miyoshi T, Hosoda H, Ma N, Yoshida T, Ikeda T.

Am J Hypertens. 2017 Dec 8;31(1):89-96. doi: 10.1093/ajh/hpx130.

PMID:
28992178
13.

Safety and dose-finding trial of tadalafil administered for fetal growth restriction: A phase-1 clinical study.

Kubo M, Tanaka H, Maki S, Nii M, Murabayashi N, Osato K, Kamimoto Y, Umekawa T, Kondo E, Ikeda T.

J Obstet Gynaecol Res. 2017 Jul;43(7):1159-1168. doi: 10.1111/jog.13345.

PMID:
28718213
14.

Retrospective study of tadalafil for fetal growth restriction: Impact on maternal and perinatal outcomes.

Kubo M, Umekawa T, Maekawa Y, Tanaka H, Nii M, Murabayashi N, Osato K, Kamimoto Y, Ikeda T.

J Obstet Gynaecol Res. 2017 Feb;43(2):291-297. doi: 10.1111/jog.13218. Epub 2016 Dec 17.

PMID:
27987345
15.

Early-onset fetal growth restriction treated with the long-acting phosphodiesterase-5 inhibitor tadalafil: a case report.

Sakamoto M, Osato K, Kubo M, Nii M, Tanaka H, Murabayashi N, Umekawa T, Kamimoto Y, Ikeda T.

J Med Case Rep. 2016 Nov 8;10(1):317.

16.

High prevalence of congenital thrombophilia in patients with pregnancy-related or idiopathic venous thromboembolism/pulmonary embolism.

Ikejiri M, Wada H, Yamada N, Nakamura M, Fujimoto N, Nakatani K, Matsuda A, Ogihara Y, Matsumoto T, Kamimoto Y, Ikeda T, Katayama N, Ito M.

Int J Hematol. 2017 Mar;105(3):272-279. doi: 10.1007/s12185-016-2111-2. Epub 2016 Oct 20.

PMID:
27766527
17.

Protection From Pregnancy Loss in Women With Hereditary Thrombophilia When Associated With Fibrinogen Polymorphism Thr331Ala.

Ikejiri M, Wada H, Kamimoto Y, Nakatani K, Ikeda T.

Clin Appl Thromb Hemost. 2017 Jul;23(5):494-495. doi: 10.1177/1076029616645400. Epub 2016 Apr 20. No abstract available.

PMID:
27099386
18.

[Pregnancy-Related Venous Thromboembolism].

Kamimoto Y, Wada H.

Rinsho Byori. 2015 Dec;63(12):1419-26. Review. Japanese.

PMID:
27089659
19.

Presence of Antiphospholipid Antibodies as a Risk Factor for Thrombotic Events in Patients with Connective Tissue Diseases and Idiopathic Thrombocytopenic Purpura.

Habe K, Wada H, Matsumoto T, Ohishi K, Ikejiri M, Matsubara K, Morioka T, Kamimoto Y, Ikeda T, Katayama N, Mizutani H.

Intern Med. 2016;55(6):589-95. doi: 10.2169/internalmedicine.55.5536. Epub 2016 Mar 15.

20.

Plasma ADAMTS13, von Willebrand Factor (VWF), and VWF Propeptide Profiles in Patients With Connective Tissue Diseases and Antiphospholipid Syndrome.

Habe K, Wada H, Matsumoto T, Ohishi K, Ikejiri M, Tsuda K, Kondo M, Kamimoto Y, Ikeda T, Katayama N, Mizutani H.

Clin Appl Thromb Hemost. 2017 Sep;23(6):622-630. doi: 10.1177/1076029615625832. Epub 2016 Jan 11.

PMID:
26759371

Supplemental Content

Loading ...
Support Center